[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"radiation-induced-mucositis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:radiation-induced-mucositis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100602664","a-randomized-controlled-study-on-the-improvement-of-medical-experience-for-patients-with-radiation-induced-oropharyngeal-mucositis-based-on-the-ris-system-of-the-internet-of-things-100602664",false,"NCT07126457","A Randomized Controlled Study on the Improvement of Medical Experience for Patients With Radiation-induced Oropharyngeal Mucositis Based on the RIS System of the Internet of Things","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form;\n2. Reached the age of 18 on the date of signing the informed consent form, and under the age of 65;\n3. Patients diagnosed with head and neck tumors and receiving radiotherapy as per the 2017 WHO standards and guidelines.\n4. According to the doctor's assessment, patients may experience radiation-induced oropharyngeal mucositis during radiotherapy.\n\nExclusion Criteria:\n\n* Have other uncontrolled serious diseases, such as unstable heart diseases requiring treatment, poorly controlled diabetes (fasting blood sugar \\> 1.5 times the upper limit of the normal value), mental disorders, and a severe history of allergies.","ALL","18 Years","65 Years",{"count":19,"type":20},110,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study is a researcher-initiated, multi-center, prospective, two-arm interventional randomized controlled study across the country. It aims to explore whether an Internet of Things-based RIS system can enhance the medical experience of patients with radiation-induced oropharyngeal mucositis during the diagnosis and treatment process among head and neck cancer patients undergoing radiotherapy.",[26,27],"Head and Neck Cancer","Radiation-Induced Mucositis",[29,26,30],"Radiation oropharyngeal mucositis","Internet of things","NOT_YET_RECRUITING","2025-08-10",{"date":34,"type":35},"2025-08-17","ACTUAL",{"date":37,"type":20},"2025-09-01",{"date":39,"type":20},"2026-12-01",{"name":41,"class":42},"Nanfang Hospital, Southern Medical University","OTHER",4,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":43},"100539706","comparative-study-of-new-classification-and-traditional-classification-of-radioactive-oropharyngeal-mucositis-100539706","NCT06307327","Comparative Study of New Classification and Traditional Classification of Radioactive Oropharyngeal Mucositis","A Comparative Study on the Evaluation Consistency Between the New Type and the Traditional Grade of Radioactive Oropharyngeal Mucositis and the Exploration of Blood Markers","Inclusion Criteria:\n\n* Voluntarily sign informed consent;\n* Age 18 or older on the date of signing the informed consent;\n* Histologically confirmed head and neck tumor, radiotherapy or chemoradiotherapy.\n\nExclusion Criteria:\n\n* They also have other uncontrolled serious medical conditions, such as unstable heart disease requiring treatment, poorly controlled diabetes (fasting blood glucose \\> 1.5× the upper limit of normal), mental illness, and a history of severe allergies",{"count":52,"type":20},264,"OBSERVATIONAL","Radiation oropharyngeal mucositis is one of the most painful side effects of radiotherapy in patients with head and neck tumors. However, the traditional radioactive oropharyngeal mucositis grading system has the problem of poor evaluation consistency. To solve this problem, we innovatively classify radiation oropharyngeal mucositis into four types according to the four-stage histopathological changes of acute radiation injury: (1) congestive; (2) Scattered erosion type; (3) Fusion erosion type; (4) Ulcer type. We intend to conduct a multicenter observational cohort study to compare the consistency of different physicians in the assessment of radiation oropharyngeal mucositis with new and traditional classifications, and to explore changes in blood markers of different types of oropharyngeal mucositis using clinical residual blood samples.",[26,27],[29,26],"RECRUITING","2025-07-13",{"date":60,"type":35},"2025-07-16",{"date":62,"type":20},"2025-09",{"date":64,"type":20},"2026-12",{"name":41,"class":42},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":21,"phases":76,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100562144","effects-of-mesenchymal-stem-cell-supernatant-on-prevention-and-treatment-of-skinmucosal-injury-in-hematology-patients-100562144","NCT06599346","Effects of Mesenchymal Stem Cell Supernatant on Prevention and Treatment of Skin\u002FMucosal Injury in Hematology Patients","Study on the Effects of Mesenchymal Stem Cell Culture Supernatant on the Prevention and Treatment of Mucosal Injury in Hematology Patients","MSC-MucInj","Inclusion Criteria:\n\n* Participants aged 18 years or older.\n* Patients who have undergone hematopoietic stem cell transplantation (HSCT).\n* Patients who have developed mucosal injuries (oral, skin, or bladder) after HSCT, chemotherapy, or radiotherapy.\n* Patients who are willing to provide informed consent and comply with the study procedures.\n\nExclusion Criteria:\n\n* Patients with severe organ dysfunction (e.g., heart, liver, kidney failure) that could interfere with the study.\n* Patients with uncontrolled active infections.\n* Known allergies or hypersensitivity to MSC supernatant.\n* Pregnant or breastfeeding women.\n* Patients with HIV or active hepatitis B or C infections.\n* Patients who have participated in another clinical trial within the last 4 weeks.",{"count":75,"type":20},120,[23],"This clinical trial is studying the effects of mesenchymal stem cell (MSC) culture supernatant on the prevention and treatment of mucosal injuries in patients undergoing hematopoietic stem cell transplantation (HSCT). HSCT is a common treatment for blood-related cancers and other serious blood disorders. However, many patients experience severe damage to their mucous membranes, including the lining of the mouth, skin, and bladder, due to the high-dose chemotherapy used in the treatment process. These mucosal injuries can cause pain, increase the risk of infection, and lower the patient's quality of life.\n\nThe purpose of this study is to determine whether MSC culture supernatant can help repair mucosal injuries and improve recovery for these patients. MSC culture supernatant contains substances produced by mesenchymal stem cells that may promote healing and reduce inflammation. These substances could potentially repair tissue without the risks associated with using live cells.\n\nParticipants in this trial will be randomly assigned to one of two groups: one group will receive standard care, and the other will receive MSC culture supernatant as part of their treatment. The study will look at how well MSC supernatant helps heal mucosal injuries, as well as its safety and any side effects that may occur. The outcomes of this study could lead to new ways to prevent and treat mucosal injuries in patients undergoing HSCT, improving their quality of life during and after treatment.\n\nThe trial will include 120 patients who have undergone HSCT and experienced mucosal injuries. The study will last approximately five years, from October 2020 to September 2025. Participants will be monitored throughout the trial for safety and effectiveness of the treatment, with follow-up visits scheduled to assess their progress.",[79,80,81,27],"Mucositis","Hematopoietic Stem Cell Transplantation","Chemotherapy-Induced Mucositis",[83,84,85,80,86,87,88,89,90,91,92,93],"Mesenchymal Stem Cell Supernatant","Mesenchymal Stem Cell Exosomes","Mucosal Injury","Chemotherapy","Radiotherapy","Oral Mucosal Injury","Skin Mucosal Injury","Bladder Injury","HSCT Complications","Tissue Regeneration","Mucosal Repair","2024-09-14",{"date":96,"type":35},"2024-09-19",{"date":98,"type":35},"2020-10-01",{"date":100,"type":20},"2025-09-30",{"name":102,"class":42},"The General Hospital of Western Theater Command",1]